Fabi Alessandra, Moscetti Luca, Ciccarese Mariangela, Caramanti Miriam, Salesi Nello, La Verde Nicla, Russillo Michelangelo, Generali Daniele, Scandurra Giuseppina, Vari Sabrina, Pacetti Umberto, Cognetti Francesco, Giannarelli Diana
Department of Medical Oncology, Regina Elena National Cancer Institute, Rome, Italy.
Future Oncol. 2015;11(3):431-8. doi: 10.2217/fon.14.271.
This multicenter study describes the effectiveness of eribulin in current practice.
PATIENTS & METHODS: In total, 78 patients with advanced metastatic breast cancer, previously treated with two or more chemotherapy lines were enrolled.
The median duration of response and disease stability were 7.5 (5.4-9.5) and 8.9 (6.2-11.6) months, respectively, with a clinical benefit (CB) at 6 months in 41% of patients. CB in visceral and nonvisceral metastases were 72.7 and 88.9%, respectively. Eribulin was active also in brain metastases, with 47% CB. The activity was shown in all biological subtypes. Toxicities were manageable.
Our study confirms the effectiveness of eribulin mesylate in the treatment of patients with metastatic breast cancer and two or more lines of chemotherapy, in particular in the good disease control at the different metastatic sites.
本多中心研究描述了艾日布林在当前临床实践中的有效性。
总共纳入了78例晚期转移性乳腺癌患者，这些患者之前接受过两种或更多化疗方案的治疗。
中位缓解持续时间和疾病稳定时间分别为7.5（5.4 - 9.5）个月和8.9（6.2 - 11.6）个月，41%的患者在6个月时具有临床获益（CB）。内脏转移和非内脏转移患者的临床获益率分别为72.7%和88.9%。艾日布林对脑转移也有活性，临床获益率为47%。在所有生物学亚型中均显示出活性。毒性是可控的。
我们的研究证实了甲磺酸艾日布林在治疗接受过两种或更多化疗方案的转移性乳腺癌患者中的有效性，特别是在不同转移部位具有良好的疾病控制效果。
